Spevigo (spesolimab-sbzo) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:		MEMBER'S FIRST NAM	MEMBER'S FIRST NAME:	
important for the review			additional documentation that is equest). Information contained in	
A STANDED WILLDAM ATTO			URGEN'	
MEMBER INFORMATIO	N	FIRST NAME.		
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRTH:	DATE OF BIRTH:	
STREET ADDRESS:		<u>'</u>		
CITY:		STATE: ZIP CO	ODE:	
PATIENT INSURANCE ID	NUMBER:	1		
IF YOU ARE NOT THE PATIENT OR THE IF FOLLOWING LINK: PRIMETHERAPEUTIC	HEIGHT (IN/CM): W PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI ES.COM/NOPP REPRESENTATIVE (IF APPLICAL	DISCLOSURE AUTHORIZATION FORM WITH THE	HIS REQUEST WHICH CAN BE FOUND AT THE	
	TATIVE'S PHONE NUMBER:			
PRESCRIBER INFORMAT	TION			
LAST NAME:		FIRST NAME:	FIRST NAME:	
PRESCRIBER SPECIALTY	:	EMAIL ADDRESS:	EMAIL ADDRESS:	
NPI NUMBER:		DEA NUMBER:	DEA NUMBER:	
PHONE NUMBER:		FAX NUMBER:	FAX NUMBER:	
STREET ADDRESS:		1		
CITY:		STATE: ZIP CO	STATE: ZIP CODE:	
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSO	OFFICE CONTACT PERSON:	
		1		
MEDICATION OR MEDI	CAL DISPENSING INFORMATIO)N		
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:	
NEW THERAPY	RENEWAL	IF RENEWAL: DATE THE	RAPY INITIATED:	
DURATION OF THERAPY	(SPECIFIC DATES):			

Continued on next page



Spevigo (spesolimab-sbzo) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST	NAME:		
1. HAS THE PATIENT TRIED ANY OTHER	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:		
2. LIST DIAGNOSES:		ICD-10:		
☐ Generalized Pustular Psoriasis☐ Other diagnosis:	ICD-10 Code(s):			
3. REQUIRED CLINICAL INFORMATION PRIOR AUTHORIZATION.	: PLEASE PROVIDE ALL RELEVANT CLINIC	AL INFORMATION TO SUPPORT A		
Is patient going to be using drug in a c	linical trial? □ Yes □ No			
Does patient weigh at least 40 kg? □ Y				
Is prescriber a dermatologist? □ Yes □ No				
Does patient have a GPPGA score of 0	or 1? □ Yes □ No			
Has patient had at least 2 presentatio provide documentation.	ns of moderate to severe GPP flare in th	e past 12months? ☐ Yes ☐ No <i>Please</i>		
Has one GPP flare had evidence of eith myalgia? Yes No Please provide of the second of the secon	her fever and/or elevated CRP and/or el documentation.	levated WBC, and/or asthenia and/or		
Is patient currently experiencing a flai	re? □ Yes □ No			
Has patient previously been treated we Please provide documentation.	vith intravenous Spevigo(spesolimab) w	ithin the <u>last 12months</u> ? Yes No		
	f the subcutaneous Spevigo(spesolimab solimab) within the <u>last 4 weeks</u> ? Yes	•		
Does patient have primary erythroder	mic psoriasis vulgaris? Yes No			
Are there any other comments, diagnormal physician feels is important to this rev	oses, symptoms, medications tried or fa riew?	iled, and/or any other information the		
Please note: Not all drugs/diagnosis ar information is received.	e covered on all plans. This request may	be denied unless all required		



Spevigo (spesolimab-sbzo) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

NACHARERIC FIRST NIABAE.

IVIEIVIBER 3 LAST NAIVIE:	IVIEIVIDER 3 FIR31 INAIVIE:			
ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that				
the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical				
information necessary to verify the accuracy of the information reported on this form.				
information necessary to verify the accuracy of the information reported on this form.				
Prescriber Signature or Electronic I.D. Verification:	Date:			
CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If				
you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents				
of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX)				
and arrange for the return or destruction of these documents.				

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program Attn:CP-4201

P.O. Box 64811 St. Paul, MN 55164-0811 Phone: 877-228-7909

Prime THERAPEUTICS*

NACNADED'S LAST NIABAE.